Table Of ContentBritish Journal of Clinical Pharmacology DOI:10.1111/4.1365-2125.2005.02460.x
AUTHOR INDEX
AARONS, L. see HUSSEIN, Z. ISBEL, N.M., PILLANS, P.I. & TETT, diproxil fumarate in HIV-1-infected
AARTS, L.P.H.J. see KNIBBE, C.A.J. S.E. Mycophenolic acid subjects: 38
AGUNDEZ, J.A.G. see MARTINEZ, C. pharmacokinetics and related outcomes BOND, C. see STEWART, D.
AKOVA, Y.A. see ALTAN-YAYCIOGLU, R. early after renal transplant: 271 BORRILL, Z.L., HOUGHTON, C.M.,
AL-ADHI, B. see AL-MOTARREB, A. ATHERTON, J. see GREEN, B. WOODCOCK, A.A., VESTBO, J. &
AL-AMOUD, A.I., CLARK, B.J., ASSI, AUMORA, B. see HOMBHANIJE, F.W. SINGH, D. Measuring bronchodilation in
K.A. & CHRYSTYN, H. Determination AUTRET-LECA, E. see BOURGOIN, H. COPD clinical trials: 379
of the bioavailability of gentamicin to BOSCH, T.M., KJELLBERG, L.M.,
the lungs following inhalation from two BABER, N. see PRITCHARD, D.S. MEIJERMAN, I., SMITS, P.H.M.,
jet nebulizers: 542 BABER, N.S. & SMYTH, R. Introduction SCHELLENS J.H.M. & BEIJNEN, J.H.
ALEMAO, E. see VAN GANSE, E. to Tripartite Meeting Report (convenors: Novel identified SNPs in the main ABC
AL-JABER, N. see AL-MOTARREB, A. Dr Nigel Baber and Prof. Ros Smyth): transporter ABCG2 (BCRP): 123
AL-JAILANI, F. see AL-MOTARREB, A. Towards establishing optimal doses for BOURBEAU, M. see VAN HEESWIJK,
ALLEGAERT, K., COSSEY, V., DEBEER, drugs prescribed to children: 655 R.P.G.
A., DEVLIEGER, H., VAN BABER, N.S. Paediatric special edition: 651 BOURGOIN, H., PAINTAUD, G.,
OVERMEIRE, B. & DE HOON, J. The BABER, N.S. Tripartite meeting. Paediatric BUCHLER, M., LEBRANCHU, Y.,
impact of ibuprofen administration on regulatory guidelines: do they help in AUTRET-LECA, E., MENTRE, F. &
amikacin clearance in preterm infants is optimizing dose selection for children?: GUELLEC, C.L. Bayesian estimation of
independent of the gestational age: 609 660 cyclosporin exposure for routine
AL-MOTARREB, A., BRIANCON, S., AL- BACK, D. see BOFFITO, M. therapeutic drug monitoring in kidney
JABER, N., AL-ADHI, B., AL-JAILANI, BACKMAN, J.T. see LILJA, J.J. transplant patients: 18
F., SALEK, M.S. & BROADLEY, K.J. BAL DIT SOLLIER, C. see MAHE, I. BREDENBERG, S. see LENNERNAS, B.
Khat chewing is a risk factor for acute BAND, M. see DAVIES, J. BRIANCON, S. see AL-MOTARREB, A.
myocardial infarction: a case-control BARNETT, D.B. see STANLEY, A.G. BROADBENT, R. see LINGVALL, M.
study: 574 BAS, M., HOFFMANN, T.K., BIER, H. & BROADLEY, K.J. see AL-MOTARREB, A.
ALTAN-YAYCIOGLU, R., YAYCIOGLU, KOJDA, G. Increased C-reactive protein BROUWERS, J.R.B.J. see DE JONG, J.C.F.
O., AKOVA, Y.A., GUVEL, S. & in ACE-inhibitor-induced angioedema: BRUNE, K. see HINZ, B.
OZKARDES, H. Ocular side-effects of 233 BUCHLER, M. see BOURGOIN, H.
tolterodine and oxybutynin, a singie- BEGGS, S. see TITCHEN, T.
blind prospective randomized trial: 588 BEIJNEN, J.H. see BOSCH, T.M. CAMERON, D.W. see VAN HEESWIJK,
AMICO, J.A. see HRUSKA, M.W. BEIJNEN, J.H. see DE JONGE, M.E. R.P.G.
AMMIT, A.J. see JIANG, X.M. BEIJNEN, J.H. see KAPPELHOFF, B.S. CAMPBELL, S.B. see ATCHESON, B.A.
ARAKAWA, M., OHMORI, M., HARADA, BENEZRA, D. /n vitro fertilization and CAULIN, C. see MAHE, I.
K.-L, ARAKI, N., SAITOH, T. & childhood retinoblastoma: 724 CH STRICKER, B.H. see SCHELLEMAN,
FUJIMURA, A. Different accumulation BENNETT, K. see TEELING, M. H.
of temocaprii and enalapril during BENNEWITH, O. see HAWTON, K. CHA, I.-J. see SHON, J.-H.
repeated dosing in elderly patients: 489 BENOWITZ, N.L. see CSAJKA, C. CHADWICK, D. see OWEN, A.
ARAKI, N. see ARAKAWA, M. BENTZEN, N. see STEINSBEKK, A. CHAIKIN, P., GILLEN, M.S., MALIK, M.,
ARONSON, J.K. Biomarkers and surrogate BERBICHE, D. see PERREAULT, S. PENTIKIS, H., RHODES, G.R. &
endpoints: 491 BERGMANN, J.F. see MAHE, I. ROBERTS, D.J. Co-administration of
ARONSON, J.K. Drug development: more BERGMANN, J.-F. see MAHE, I. ketoconazole with H,-antagonists
science, more education: 377 BERTRAND, M. see VAN GANSE, E. ebastine and loratadine in healthy
ARONSON, J.K. Internationality: | BERTRAND, N. see MAHE, I. subjects: pharmacokinetic and
ARONSON, J.K. Moving about: 263 BIER, H. see BAS, M. pharmacodynamic effects: 346
ARONSON, J.K. see FERNER, R.E. BJORKMAN, S. Prediction of drug CHALASANI, N. see PINTO, A.G.
ARONSON, J.K. Write on: 141 disposition in infants and children by CHAN, F.W.H. see YOU, J.HLS.
ASGHAR, A. see PINTO, A.G. means of physiologically based CHAPPUY, H. see JULLIEN, V.
ASHTON, M. see GORDI, T. pharmacokinetic (PBPK) modelling: CHEN, X.Y. see ZHANG, Y.F.
ASSI, K.A. see AL-AMOUD, A.IL. theophylline and midazolam as model CHENG, G. see YOU, J.H.S.
ASTRUC, B., TARRAL, A., DOSTERT, P., drugs: 691 CHEUNG, B.M.Y. see HUI, C.K.
MARIOTTI, F., FABBRI, L. & BLAIS, L. see PERREAULT, S. CHEUNG, Y.-B. see ZHOU, Q.Y.
IMBIMBO, B.P. Steady-state BLANCO, G. see MARTINEZ, C. CHEVTS, J. see HINZ, B.
pharmacokinetics and pharmacodynamics BOFFITO, M., BACK, D., STAINSBY- CHOWBAY, B. see ZHOU, Q.Y.
of CHF3381, a novel antineuropathic TRON, M., HILL, A., PERRI, G.D., CHRYSTYN, H. see AL-AMOUD, A.1.
pain agent, in healthy subjects: 405 MOYLE, G., NELSON, M., TOMKINS, CHUI, J.. TORDOFF, J. & REITH, D.
ATARASHL, S. see PAYNE, G.S. J., GAZZARD, B. & POZNIAK, A. Changes in availability of paediatric
ATCHESON, B.A., TAYLOR, P.J., Pharmacokinetics of saquinavir hard medicines in Australia between 1998 and
MUDGE, D.W., JOHNSON, D.W., gel/ritonavir (1000/10m0g twice daily) 2002: 736
HAWLEY, C.M., CAMPBELL, S.B., when administered with tenofovir CLARK, B.J. see AL-AMOUD, A.I.
BJr Cl in Pharmacol | 59:6 | 756-761
© 2005 Blackwell Publishing Ltd
British Journal of Clinical Pharmacology DOI:10.1111/4.1365-2125.2005.02460.x
AUTHOR INDEX
AARONS, L. see HUSSEIN, Z. ISBEL, N.M., PILLANS, P.I. & TETT, diproxil fumarate in HIV-1-infected
AARTS, L.P.H.J. see KNIBBE, C.A.J. S.E. Mycophenolic acid subjects: 38
AGUNDEZ, J.A.G. see MARTINEZ, C. pharmacokinetics and related outcomes BOND, C. see STEWART, D.
AKOVA, Y.A. see ALTAN-YAYCIOGLU, R. early after renal transplant: 271 BORRILL, Z.L., HOUGHTON, C.M.,
AL-ADHI, B. see AL-MOTARREB, A. ATHERTON, J. see GREEN, B. WOODCOCK, A.A., VESTBO, J. &
AL-AMOUD, A.I., CLARK, B.J., ASSI, AUMORA, B. see HOMBHANIJE, F.W. SINGH, D. Measuring bronchodilation in
K.A. & CHRYSTYN, H. Determination AUTRET-LECA, E. see BOURGOIN, H. COPD clinical trials: 379
of the bioavailability of gentamicin to BOSCH, T.M., KJELLBERG, L.M.,
the lungs following inhalation from two BABER, N. see PRITCHARD, D.S. MEIJERMAN, I., SMITS, P.H.M.,
jet nebulizers: 542 BABER, N.S. & SMYTH, R. Introduction SCHELLENS J.H.M. & BEIJNEN, J.H.
ALEMAO, E. see VAN GANSE, E. to Tripartite Meeting Report (convenors: Novel identified SNPs in the main ABC
AL-JABER, N. see AL-MOTARREB, A. Dr Nigel Baber and Prof. Ros Smyth): transporter ABCG2 (BCRP): 123
AL-JAILANI, F. see AL-MOTARREB, A. Towards establishing optimal doses for BOURBEAU, M. see VAN HEESWIJK,
ALLEGAERT, K., COSSEY, V., DEBEER, drugs prescribed to children: 655 R.P.G.
A., DEVLIEGER, H., VAN BABER, N.S. Paediatric special edition: 651 BOURGOIN, H., PAINTAUD, G.,
OVERMEIRE, B. & DE HOON, J. The BABER, N.S. Tripartite meeting. Paediatric BUCHLER, M., LEBRANCHU, Y.,
impact of ibuprofen administration on regulatory guidelines: do they help in AUTRET-LECA, E., MENTRE, F. &
amikacin clearance in preterm infants is optimizing dose selection for children?: GUELLEC, C.L. Bayesian estimation of
independent of the gestational age: 609 660 cyclosporin exposure for routine
AL-MOTARREB, A., BRIANCON, S., AL- BACK, D. see BOFFITO, M. therapeutic drug monitoring in kidney
JABER, N., AL-ADHI, B., AL-JAILANI, BACKMAN, J.T. see LILJA, J.J. transplant patients: 18
F., SALEK, M.S. & BROADLEY, K.J. BAL DIT SOLLIER, C. see MAHE, I. BREDENBERG, S. see LENNERNAS, B.
Khat chewing is a risk factor for acute BAND, M. see DAVIES, J. BRIANCON, S. see AL-MOTARREB, A.
myocardial infarction: a case-control BARNETT, D.B. see STANLEY, A.G. BROADBENT, R. see LINGVALL, M.
study: 574 BAS, M., HOFFMANN, T.K., BIER, H. & BROADLEY, K.J. see AL-MOTARREB, A.
ALTAN-YAYCIOGLU, R., YAYCIOGLU, KOJDA, G. Increased C-reactive protein BROUWERS, J.R.B.J. see DE JONG, J.C.F.
O., AKOVA, Y.A., GUVEL, S. & in ACE-inhibitor-induced angioedema: BRUNE, K. see HINZ, B.
OZKARDES, H. Ocular side-effects of 233 BUCHLER, M. see BOURGOIN, H.
tolterodine and oxybutynin, a singie- BEGGS, S. see TITCHEN, T.
blind prospective randomized trial: 588 BEIJNEN, J.H. see BOSCH, T.M. CAMERON, D.W. see VAN HEESWIJK,
AMICO, J.A. see HRUSKA, M.W. BEIJNEN, J.H. see DE JONGE, M.E. R.P.G.
AMMIT, A.J. see JIANG, X.M. BEIJNEN, J.H. see KAPPELHOFF, B.S. CAMPBELL, S.B. see ATCHESON, B.A.
ARAKAWA, M., OHMORI, M., HARADA, BENEZRA, D. /n vitro fertilization and CAULIN, C. see MAHE, I.
K.-L, ARAKI, N., SAITOH, T. & childhood retinoblastoma: 724 CH STRICKER, B.H. see SCHELLEMAN,
FUJIMURA, A. Different accumulation BENNETT, K. see TEELING, M. H.
of temocaprii and enalapril during BENNEWITH, O. see HAWTON, K. CHA, I.-J. see SHON, J.-H.
repeated dosing in elderly patients: 489 BENOWITZ, N.L. see CSAJKA, C. CHADWICK, D. see OWEN, A.
ARAKI, N. see ARAKAWA, M. BENTZEN, N. see STEINSBEKK, A. CHAIKIN, P., GILLEN, M.S., MALIK, M.,
ARONSON, J.K. Biomarkers and surrogate BERBICHE, D. see PERREAULT, S. PENTIKIS, H., RHODES, G.R. &
endpoints: 491 BERGMANN, J.F. see MAHE, I. ROBERTS, D.J. Co-administration of
ARONSON, J.K. Drug development: more BERGMANN, J.-F. see MAHE, I. ketoconazole with H,-antagonists
science, more education: 377 BERTRAND, M. see VAN GANSE, E. ebastine and loratadine in healthy
ARONSON, J.K. Internationality: | BERTRAND, N. see MAHE, I. subjects: pharmacokinetic and
ARONSON, J.K. Moving about: 263 BIER, H. see BAS, M. pharmacodynamic effects: 346
ARONSON, J.K. see FERNER, R.E. BJORKMAN, S. Prediction of drug CHALASANI, N. see PINTO, A.G.
ARONSON, J.K. Write on: 141 disposition in infants and children by CHAN, F.W.H. see YOU, J.HLS.
ASGHAR, A. see PINTO, A.G. means of physiologically based CHAPPUY, H. see JULLIEN, V.
ASHTON, M. see GORDI, T. pharmacokinetic (PBPK) modelling: CHEN, X.Y. see ZHANG, Y.F.
ASSI, K.A. see AL-AMOUD, A.IL. theophylline and midazolam as model CHENG, G. see YOU, J.H.S.
ASTRUC, B., TARRAL, A., DOSTERT, P., drugs: 691 CHEUNG, B.M.Y. see HUI, C.K.
MARIOTTI, F., FABBRI, L. & BLAIS, L. see PERREAULT, S. CHEUNG, Y.-B. see ZHOU, Q.Y.
IMBIMBO, B.P. Steady-state BLANCO, G. see MARTINEZ, C. CHEVTS, J. see HINZ, B.
pharmacokinetics and pharmacodynamics BOFFITO, M., BACK, D., STAINSBY- CHOWBAY, B. see ZHOU, Q.Y.
of CHF3381, a novel antineuropathic TRON, M., HILL, A., PERRI, G.D., CHRYSTYN, H. see AL-AMOUD, A.1.
pain agent, in healthy subjects: 405 MOYLE, G., NELSON, M., TOMKINS, CHUI, J.. TORDOFF, J. & REITH, D.
ATARASHL, S. see PAYNE, G.S. J., GAZZARD, B. & POZNIAK, A. Changes in availability of paediatric
ATCHESON, B.A., TAYLOR, P.J., Pharmacokinetics of saquinavir hard medicines in Australia between 1998 and
MUDGE, D.W., JOHNSON, D.W., gel/ritonavir (1000/10m0g twice daily) 2002: 736
HAWLEY, C.M., CAMPBELL, S.B., when administered with tenofovir CLARK, B.J. see AL-AMOUD, A.I.
BJr Cl in Pharmacol | 59:6 | 756-761
© 2005 Blackwell Publishing Ltd
Author Index |
CLAUSON, P. see MCELDUFF, A. DIMET, J. see JULLIEN, V. GLOTH, F.M. Handbook of pain relief in
COCKAYNE, N.L., DUGUID, M. & DOSTERT, P. see ASTRUC, B. older adults — an evidence-based
SHENFIELD, G.M. Health professionals DRAGOMIR, A. see PERREAULT, S. approach: 262
rarely record history of complementary DRESCHER, S. see GLAESER, H. GOSSL, M. see SAEZ, A.M.O.
and alternative medicines: 254 DROUET, L. see MAHE, I. GOLDRING, C. see OWEN, A.
COCKBURN, W. see LIPWORTH, B.J. DUGUID, M. see COCKAYNE, N.L. GORDI, T., XIE, R., HUONG, N.V.,
COHEN, A.F. see DUMONT, G.J.H. DUKE, C.C. see JIANG, X.M. HUONG, D.X., KARLSSON, M.O. &
COLLIN, J. see PERREAULT, S. DUMONT, G.J.H., DE VISSER, S.J., ASHTON, M. A semiphysiological
COLLINS, D.J. see PAYNE, G.S. COHEN, A.F. & VAN GERVEN, J.M.A. pharmacokinetic model for artemisinin in
CONTI, R. see MAHE, I. Biomarkers for the effects of selective healthy subjects incorporating
COPETTI, R., PROCLEMER, A. & serotonin reuptake inhibitors (SSRIs) in autoinduction of metabolism and
PILLININI, P.P. Brugada-like ECG healthy subjects: 495 saturable first-pass hepatic extraction:
abnormalities during thioridazine DUPIN, N. see JULLIEN, V. 189
overdose DZIK-JURASZ, A.S.K. see PAYNE, G.S. GREEN, B., GREENWOOD, M..,
COSSEY, V. see ALLEGAERT, K. SALTISSI, D., WESTHUYZEN, J.,
CRANSWICK, N. see TITCHEN, T. EARL, J.W. see NATH, C.E. KLUVER, L., ROWELL, J. &
CROMMENTUYN, K.MLL. see EBRAHIM, S. see WALLER, P. ATHERTON, J. Dosing strategy for
KAPPELHOFF, B.S. EICHELBAUM, M. see GLAESER, H. enoxaparin in patients with renal
CSAJKA, C., HALLER, C.A., BENOWITZ, EICHELBAUM, M. see NIEMI M. impairment presenting with acute
N.L. & VEROTTA, D. Mechanistic EKINS-DAUKES, S. see NOVAK, P.H. coronary syndromes: 281
pharmacokinetic modelling of ephedrine, EKINS-DAUKES, S., HELMS, P.J., GREENWOOD, M. see GREEN, B.
norephedrine and caffeine in healthy TAYLOR, M.W., SIMPSON, C.R. & GREIG, L.D., LESLIE, S.J., GIBB, F.W..,
subjects McLAY, J.S. Paediatric homoeopathy in TAN, S., NEWBY, D.E. & WEBB, D.J.
CZOCK, D., KELLER, F., HERINGA, M. general practice: where, when and why?: Comparative effects of glyceryl trinitrate
& RASCHE, F.M. Raloxifene 743 and amyl nitrite on pulse wave reflection
pharmacokinetics in males with normal ELLIOT, R. see SORENSEN, L. and augmentation index: 265
and impaired renal function: 479 GRIEVE, J., TORDOFF, J., REITH, D. &
FONNEB@, V. see STEINSBEKK, A. NORRIS, P. Effect of the Pediatric
DANHOF, M. see KNIBBE, C.A.J. FABBRI, L. see ASTRUC, B. Exclusivity Provision on children’s
DARTIGUES, J.-F. see LECHEVALLIER- FABRIGOULE, C. see LECHEVALLIER- access to medicines: 730
MICHEL, N. MICHEL, N. GROENEVELD, G.J. see VAN KAN,
DAUKES, S.E. see HELMS, P.J. FEELY, J. see TEELING, M. H.J.M.
DAVE, N. see SNELL, P. FERNER, R.E. & ARONSON, J.K. National GROVER, A. see SHAFIQ, N.
DAVIES, J., GAVIN, A., BAND, M., differences in publishing papers on GUCHELAAR, H.J. see VAN KAN, H.J.M.
MORRIS, A. & STRUTHERS, A. adverse drug reactions: 108 GUELLEC, C.L. see BOURGOIN, H.
Spironolactone reduces brachial pulse FERRELL, R.E. see HRUSKA, M.W. GUNNELL, D. see HAWTON, K.
wave velocity and PIIINP levels in FISHMAN, R. see LIPWORTH, B.J. GUO, Y.J. see ZHANG, Y.F.
hypertensive diabetic patients: 520 FITZGERALD, M. see WEEKES, L.M. GUVEL, S. see ALTAN-YAYCIOGLU, R.
DAY, R.O. see JIANG, X.M. FITZGERALD, S.M. see HRUSKA, M.W.
DE BOER, A. see SCHELLEMAN, H. FOURRIER-REGLAT, A. see HALL, S.D. see PINTO, A.G.
DE HOON, J. see ALLEGAERT, K. LECHEVALLIER-MICHEL, N. HALLER, C.A. see CSAJKA, C.
DE HOON, J.N.J.M. see VANMOLKOT, FROMM, M.F. see GLAESER, H. HAMMAN, M. see PINTO, A.G.
F.H.M. FROMM, M.F. see NIEMI M. HAQUE, N. see PAYNE, G.S.
DE JONG, J.C.F., BROUWERS, J.R.B.J. & FRYE, R.F. see HRUSKA, M.W. HARADA, K.-I. see ARAKAWA, M.
DE JONG-VAN DEN BERG, L.T.W. FUJIMURA, A. see ARAKAWA, M. HAUG-PIHALE, G. see SOBUE, S.
Combined use of NSAIDs and SSRIs FUJIMURA, A. see WAKAUMI, M. HAWLEY, C.M. see ATCHESON, B.A.
increases the risk for gastrointestinal HAWTON, K., SIMKIN, S., GUNNELL,
adverse effects: 119 GALITZ, L. see SNELL, P. D., SUTTON, L., BENNEWITH, O.,
DE JONGE, M.E., HUITEMA, A.D.R., GAMITO, F.J.G. see MARTINEZ, C. TURNBULL, P. & KAPUR, N. A
SCHELLENS, J.H.M., RODENHUIS, S. GARBER, G.E. see VAN HEESWIJK, multicentre study of coproxamol
& BEIJNEN, J.H. Population R.P.G. poisoning suicides based on coroners’
pharmacokinetics of orally administered GARCIA-MARTIN, E. see MARTINEZ, C. records in England: 207
paclitaxel formulated in Cremophor EL: GAUDRIC, A. see MAHE, I. HEDNER, T. see LENNERNAS, B.
325 GAVIN, A. see DAVIES, J. HELMS, P. see NOVAK, P.H.
DE JONG-VAN DEN BERG, L.T.W. see GAZZARD, B. see BOFFITO, M. HELMS, P. see STEWART, D.
DE JONG, J.C.F. GIBB, F.W. see GREIG, L.D. HELMS, P.J. see EKINS-DAUKES, S.
DE LA IGLESIA, F.A. see SMITH, M.T. GIGUERE, P. see VAN HEESWIJK, HELMS, P.J., DAUKES, S.E., TAYLOR,
DE PONTI, F. see MOTOLA, D. R.P.G. M.W., SIMPSON, C.R. & McLAY, J.S.
DE POUVOURVILLE, G. see VAN GILLEN, M.S. see CHAIKIN, P. Utility of routinely acquired primary care
GANSE, E. GLAESER, H., DRESCHER, S., data for paediatric disease epidemiology
DE VISSER, S.J. see DUMONT, G.J.H. EICHELBAUM, M. & FROMM, M.F. and pharmacoepidemiology: 684
DEBEER, A. see ALLEGAERT, K. Influence of rifampicin on the expression HEMPEL, G. Handbook of analytical
DELESEN, H. see STASS, H. and function of human intestinal separations, vol. 5: drug monitoring and
DEVLIEGER, H. see ALLEGAERT, K. cytochrome P450 enzymes: 199 clinical chemistry: 605
BrJ Clin Pharmacol | 59:6 | 757
| Author Index
HERINGA, M. see CZOCK, D. IMBIMBO, B.P. see ASTRUC, B. KIVISTO K.T. see NIEMI M.
HERRMANN N. see JUURLINK, D.N. ISBEL, N.M. see ATCHESON, B.A. KJELLBERG, L.M. see BOSCH, T.M.
HERTTUAINEN, J. see LAHELMA, S. ISHIZAKI, T. see HOMBHANIE, F.W. KLONER, R.A. Heart disease and erectile
HILL, A. see BOFFITO, M. dysfunction: 375
HINZ, B., CHEVTS, J., RENNER, B., JACKSON, D. see STANLEY, A.G. KLUNGEL, O.H. see SCHELLEMAN, H.
WUTTKE, H., RAU, T., SCHMIDT, A., JANNUZZO, M.G. see VALLE, M. KLUVER, L. see GREEN, B.
SZELENYI, L, BRUNE, K. & JARRIN, I. see MAHE, I. KNIBBE, C.A.J., ZUIDEVELD, K.P.,
WERNER, U. Bioavailability of JIANG, X.M., WILLIAMS, K.M., LIAUW, AARTS, L.P.H.J., KUKS, P.F.M. &
diclofenac potassium at low doses: 80 W.S., AMMIT, A.J., ROUFOGALIS, DANHOF, M. Allometric relationships
HO, D. see WALLER, P. B.D., DUKE, C.C., DAY, R.O. & between the pharmacokinetics of
HOFFMANN, T.K. see BAS, M. MCLACHLAN, A.J. Effect of ginkgo propofol in rats, children and adults:
HOFMAN, A. see SCHELLEMAN, H. and ginger on the pharmacokinetics and 705
HOFMANN, U. see NIEMI M. pharmacodynamics of warfarin in healthy KOBAYAKAWA, T. see HOMBHANIJE,
HOLMBERG, M. see LENNERNAS, B. subjects: 425 FW.
HOMBHANJE, F.W., HWAIHWANIJE, L., JOHNSON, D.W. see ATCHESON, B.A. KOIDA, G. see BAS, M.
TSUKAHARA, T., SARUWATARI, J., JOHNSON, T.N. Modelling approaches to KOLWANKAR, D. see PINTO, A.G.
NAKAGAWA, M., OSAWA, H., PANIU, dose estimation in children: 663 KOPP, A. see JUURLINK, D.N.
M.M., TAKAHASHI, N., LUM, J.K., JULLIEN, V., TRELUYER, J.-M., KUBITZA, D. see STASS, H.
AUMORA, B., MASTA, A., SAPURI, CHAPPUY, H., DIMET, J., REY, E., KUKS, P.F.M. see KNIBBE, C.A.J.
M., KOBAYAKAWA, T., KANEKO, A. DUPIN, N., SALMON, D., PONS, G. &
& ISHIZAKI, T. The disposition of oral URIEN, S. Weight related differences in LAHELMA, S., KIRJAVAINEN, M., KELA,
amodiaquine in Papua New Guinean the pharmacokinetics of abacavir in HIV- M., HERTTUAINEN, J., VAHTERISTO,
children with falciparum malaria: 298 infected patients: 183 M., SILVASTI, M. & RANKI-
HORLANDER, J. see PINTO, A.G. JUURLINK, D.N., MAMDANI, M.M., PESONEN, M. Equivalent lung
HOUGHTON, C.M. see BORRILL, Z.L. KOPP, A., HERRMANN N. & deposition of budesonide in vivo: a
HOUGHTON, C.M., WCODCOCK, A.A. & LAUPACIS, A. A population-based comparison of dry powder inhalers using
SINGH, D. A comparison of assessment of the potential interaction a pharmacokinetic method: 167
plethysmography, spirometry and between serotonin-specific reuptake LADD, L.A., KAM, P.C., WILLIAMS,
oscillometry for assessing the pulmonary inhibitors and digoxin: 102 D.B., WRIGHT, A.W.E., SMITH, M.T.
effects of inhaled ipratropium bromide in & MATHER, L.E. Ventilatory responses
healthy subjects and patients with KALMIJN, S. see VAN KAN, H.J.M. of healthy subjects to intravenous
asthma: 152 KAM, P.C. see LADD, L.A. combinations of morphine and
HRUSKA, M.W., AMICO, J.A., KAM, P.C. see MCELDUFF, A. oxycodone under imposed hypercapnic
LANGAEE, T.Y., FERRELL, R.E., KAMALI, F. see SCONCE, E.A. and hypoxaemic conditions: 524
FITZGERALD, S.M. & FRYE, R.F. The KANEKO, A. see HOMBHANIJE, F.W. LADERO, J.M. see MARTINEZ, C.
effect of trimethoprim on CYP2C8 KAPPELHOFF, B.S., HUITEMA, A.D.R., LAFOREST, L. see VAN GANSE, E.
mediated rosiglitazone metabolism in CROMMENTUYN, K.M.L., MULDER, LALONDE, L. see PERREAULT, S.
human liver microsomes and healthy J.W., MEENHORST, P.L., VAN GORP, LAMARRE, D. see PERREAULT, S.
subjects: 70 E.C.M., MAIRUHU, A.T.A. & LANGAEE, T.Y. see HRUSKA, M.W.
HUGHES, D.M. see KERNOHAN, A.F.B. BEIJNEN, J.H. Development and LAU, G.K.K. see HUI, C.K.
HUI, C.K., CHEUNG, B.M.Y. & LAU, validation of a population LAUPACIS, A. see JUURLINK, D.N.
G.K.K. Pharmacokinetics of pitavastatin pharmacokinetic model for ritonavir used LAURIER, C. see PERREAULT, S.
in subjects with Child-Pugh A and B as a booster or as an antiviral agent in LAVORINI F. Quantifying bronchodilator
cirrhosis: 291 HIV-1-infected patients: 174 responses in chronic obstructive
HUITEMA, A.D.R. see DE JONGE, M.E. KAPUR, N. see HAWTON, K. pulmonary disease trials: 385
HUITEMA, A.D.R. see KAPPELHOFF, B.S. KARLSSON, M.O. see GORDI, T. LE JEUNNE, P. see VAN GANSE, E.
HUONG, D.X. see GORDI, T. KELA, M. see LAHELMA, S. LEACH, M.O. see PAYNE, G:S.
HUONG, N.V. see GORDI, T. KELLER, F. see CZOCK, D. LEBRANCHU, Y. see BOURGOIN, H.
HUSSEIN, Z., PITSIU, M., MAJID, O., KERNOHAN, A.F.B., MCINTYRE, M., LECHEVALLIER-MICHEL, N.,
AARONS, L., LONGUEVILLE, M.D. & HUGHES, D.M., TAM, S.W., WORCEL, MOLIMARD, M., DARTIGUES, J.-F.,
STOCKIS, A. on behalf of the ETAC’ M. & REID, J.L. An oral yohimbine/L- FABRIGOULE, C. & FOURRIER-
Study Group Retrospective population arginine combination (NMI 861) for the REGLAT, A. Drugs with anticholinergic
pharmacokinetics of levocetirizine in treatment of male erectile dysfunction: a properties and cognitive performance in
atopic children receiving cetirizine: the pharmacokinetic, pharmacodynamic and the elderly: results from the PAQUID
ETAC” study: 28 interaction study with intravenous Study: 143
HWAIHWANIJE, I. see HOMBHANSE, F.W. nitroglycerine in healthy male subjects: LEE, A. see ZHOU, Q.Y.
85 LEE, C.H. see SHON, J.-H.
IGARASHI, T. see SARASHINA, A. KESSAR, P. see PAYNE, G.S. LEE, E.J.D. see ZHOU, Q.Y.
IKEDA, H., MURAKAMI, T., TAKANO, KHAN, T.l. see SCONCE, E.A. LENNERNAS, B., HEDNER, T.,
M., USUI, T. & KIHIRA, K. KHAZAAL, Y. see ZULLINO, D.F. HOLMBERG, M., BREDENBERG, S.,
Pharmacokinetic interaction on valproic KIHIRA, K. see IKEDA, H. NYSTROM, C. & LENNERNAS, H.
acid and recurrence of epileptic seizures KIM, K.-A. see SHON, J.-H. Pharmacokinetics and tolerability of
during chemotherapy in an epileptic KIM, M.-J. see SHON, J.-H. different doses of fentanyl following
patient: 593 KIRJAVAINEN, M. see LAHELMA, S. sublingual administration of a rapidly
758 | 59:6 | BrJ Clin Pharmacol
eRe eLR
dissolving tablet to cancer patients: a MARTINEZ, C., GARCIA-MARTIN, E., NELSON, M. see BOFFITO, M.
new approach to treatment of incident BLANCO, G., GAMITO, F.J.G., NEUVONEN, P.J. see LILJA, J.J.
pain: 249 LADERO, J.M. & AGUNDEZ, J.A.G. NEWBY, D.E. see GREIG, L.D.
LENNERNAS, H. see LENNERNAS, B. The effect of the cytochrome P450 NIEMI, M., KIVISTO, K.T., HOFMANN,
LESLIE, S.J. see GREIG, L.D. CYP2C8 polymorphism on the U., SCHWAB, M., EICHELBAUM, M.
LEWITH, G. see STEINSBEKK, A. disposition of (R)-ibuprofen enantiomer & FROMM, M.F. Fexofenadine
LIAUW, W.S. see JIANG, X.M. in healthy subjects: 69 pharmacokinetics are associated with a
LILJA, J.J.. BACKMAN, J.T. & MARTINI, N. see MOTOLA, D. polymorphism of the SLCO/B/ gene
NEUVONEN, P.J. Effect of gemfibrozil MASON, J. see SCONCE, E.A. (encoding OATP1B1): 602
on the pharmacokinetics and MASTA, A. see HOMBHANJE, F.W. NOBLE, F. see SCONCE, E.A.
pharmacodynamics of racemic warfarin MATHER, L.E. see LADD, L.A. NORRIS, P. see GRIEVE, J.
in healthy subjects: 433 MATHER, L.E. see MCELDUFF, A. NOVAK, P.H., EKINS-DAUKES, S..,
LIM, Y.-C. see SHON, J.-H. MAZOYER, E. see MAHE, I. SIMPSON, C.R., MILNE, R.M.,
LINGVALL, M., REITH, D. & McCAIG, D. see STEWART, D. HELMS, P. & McLAY, J.S. Acute drug
BROADBENT, R. The effect of sepsis MCELDUFF, A., MATHER, L.E., KAM, prescribing to children on chronic
upon gentamicin pharmacokinetics in P.C. & CLAUSON, P. Influence of acute antiepilepsy therapy and the potential for
neonates: 54 upper respiratory tract infection on the adverse drug interactions in primary
LIPWORTH, B.J., SIMS, E.J. TAYLOR, K., absorption of inhaled insulin using the care: 712
COCKBURN, W. & FISHMAN, R. AERx” insulin Diabetes Management NURNBERGER, J. see SAEZ, A.M.O.
Dose-response to salbutamol via a novel System: 546 NUNN, T. & WILLIAMS, J. Formulation of
palm sized nebuliser (Aerodose™ Inhaler), MCINTYRE, M. see KERNOHAN, A.F.B. medicines for children: 674
conventional nebuliser (Pari LC Plus) MCLACHLAN, A.J. see JIANG, X.M. NYSTROM, C. see LENNERNAS, B.
and metered dose inhaler (Ventolin™ McLAY, J. see STEWART, D.
Evohaler™) in moderate to severe McLAY, J.S. see EKINS-DAUKES, S. OHMORI, M. see ARAKAWA, M.
asthmatics: 5 McLAY, J.S. see HELMS, P.J. OSAWA, H. see HOMBHANIJE, F.W.
LIU, K.-H. see SHON, J.-H. McLAY, J.S. see NOVAK, P.H. OTERO, J. see MAHE, I.
LOBOZ, K.K. & SHENFIELD, G.M. Drug MEENHORST, P.L. see KAPPELHOFF, OWEN, A., GOLDRING, C., MORGAN, P.,
combinations and impaired renal function B.S. CHADWICK, D., PARK, B.K. &
— the ‘triple whammy’: 239 MEIJERMAN, I. see BOSCH, T.M. PIRMOHAMED, M. Relationship
LONGUEVILLE, M.D. see HUSSEIN, Z. MENTRE, F. see BOURGOIN, H. between the C,35T and Gy_77T(A)
LOYNDS, P. see PAYNE, G.S. MESKI, S.E. see MAHE, I. polymorphisms in the ABCB/ gene and
LUM, J.K. see HOMBHANIJE, F.W. MILNE, R.M. see NOVAK, P.H. P-glycoprotein expression in human
MITCHELL, A. see SAEZ, A.M.O. liver: 365
MACKSON, J.M. see WEEKES, L.M. MOLLER, J.-G. see STASS, H. OZKARDES, H. see ALTAN-YAYCIOGLU,
MAHE, I., BERTRAND, N., DROUET, L., MOLIMARD, M. see LECHEVALLIER- R.
SIMONEAU, G., MAZOYER, E., BAL MICHEL, N.
DIT SOLLIER, C., CAULIN, C. & MONTANARO, N. see MOTOLA, D. PAINTAUD, G. see BOURGOIN, H.
BERGMANN, J.F. Paracetamol: a MONTGOMERY, K. see NATH, C.E. PANDHI, P. see SHAFIQ, N.
haemorrhagic risk factor in patients on MORGAN, P. see OWEN, A. PANIU, M.M. see HOMBHANJE, F.W.
warfarin: 371 MORRIS, A. see DAVIES, J. PARK, B.K. see OWEN, A.
MAHE, I., MOULY, S., JARRIN, I., MOSEL, F. see SAEZ, A.M.O. PAYNE, G.S., COLLINS, D.J., LOYNDS,
OTERO, J., TAVERA, C., SIMONEAU, MOTOLA, D., DE PONTI, F., ROSSI, P., P., MOULD, G., MURPHY, P.S., DZIK-
G., TILLET, Y., CONTI, R., MESKI, MARTINI, N. & MONTANARO, N. JURASZ, A.S.K., KESSAR, P., HAQUE,
S.E., GAUDRIC, A. & BERGMANN, Therapeutic innovation in the European N., YAMAGUCHI, M., ATARASHI, S.
J.-F. Efficacy and safety of three Union: analysis of the drugs approved by & LEACH, M.O. Quantitative
ophthalmic inserts for topical anaesthesia the EMEA between 1995 and 2003: 475 assessment of the hepatic
of the cornea. An exploratory MOULD, G. see PAYNE, G.S. pharmacokinetics of the antimicrobial
comparative dose-ranging, double-blind, MOULIN, P. see VAN GANSE, E. sitafloxacin in humans using in vivo °F
randomized trial in healthy volunteers: MOULY, S. see MAHE, I. magnetic resonance spectroscopy: 244
220 MOYLE, G. see BOFFITO, M. PENTIKIS, H. see CHAIKIN, P.
MAIRUHU, A.T.A. see KAPPELHOFF, MUDGE, D.W. see ATCHESON, B.A. PERREAULT, S., BLAIS, L., LAMARRE,
B.S. MULDER, J.W. see KAPPELHOFF, B.S. D., DRAGOMIR, A., BERBICHE, D.,
MAJID, O. see HUSSEIN, Z. MUNAKATA, A. see SAITO, M. LALONDE, L., LAURIER, C., ST-
MALHOTRA, S. see SHAFIQ, N. MURAKAMI, T. see IKEDA, H. MAURICE, F. & COLLIN, J. Persistence
MALIK, M. see CHAIKIN, P. MURPHY, P.S. see PAYNE, G.S. and determinants of statin therapy among
MAMDANI, M.M. see SUURLINK, D.N. MURRAY, M.L. see WONG, I.C.K. middle-aged patients for primary and
MARIOTTI, F. see ASTRUC, B. secondary prevention: 564
MARTINEZ, C., GARCIA-MARTIN, E., NAKAGAWA, M. see HOMBHANGJE, F.W. PERRI, G.D. see BOFFITO, M.
BLANCO, G., GAMITO, F.J.G., NATH, C.E., SHAW, P.J.. MONTGOMERY, PHILIPP, T. see SAEZ, A.M.O.
LADERO, J.M. & AGUNDEZ, J.A.G. K. & EARL, J.W. Melphalan PHILLIPS, S.R. see WEEKES, L.M.
The effect of the cytochrome P450 pharmacokinetics in children with PILLANS, P.I. see ATCHESON, B.A.
CYP2C8 polymorphism on the malignant disease: influence of body PILLININI, P.P. see COPETTI, R.
disposition of (R)-ibuprofen enantiomer weight, renal function, carboplatin PINTO, A.G., HORLANDER, J.,
in healthy subjects: 62 therapy and total body irradiation: 314 CHALASANI, N., HAMMAN, M.,
BrJ Clin Pharmacol | 59:6 | 759
| Author Index
ASGHAR, A., KOLWANKAR, D. & SAITOH, T. see ARAKAWA, M. SINGH, D. see BORRILL, Z.L.
HALL, S.D. Diltiazem inhibits human SAKAMOTO, K. see WAKAUMI, M. SINGH, D. see HOUGHTON, C.M.
intestinal cytochrome P450 3A (CYP3A) SALEK, M.S. see AL-MOTARREB, A. SMITH, M.T. & DE LA IGLESIA, F.A. Co-
activity in vivo without altering the SALLE, E.D. see VALLE, M. administration of oxycodone and
expression of intestinal mRNA or SALMON, D. see JULLIEN, V. morphine and analgesic synergy re-
protein: 440 SALTISSI, D. see GREEN, B. examined: 486
PIRMOHAMED, M. see OWEN, A. SAPURI, M. see HOMBHANIJE, F.W. SMITH, M.T. see LADD, L.A.
PITSIU, M. see HUSSEIN, Z. SARASHINA, A., TATAMI, S., SMITS, P.H.M. see BOSCH, T.M.
POGGESI, I. see VALLE, M. YAMAMURA, N., TSUDA, Y. & SMYTH, R. see BABER, N.S.
PONS, G. see JULLIEN, V. IGARASHI, T. Population SNELL, P., DAVE, N., WILSON, K.,
POON, D. see ZHOU, Q.Y. pharmacokinetics of epinastine, a ROWELL, L., WEIL, A., GALITZ, L. &
POZNIAK, A. see BOFFITO, M. histamine H, receptor antagonist, in ROBSON, R. Lack of effect of moderate
PRITCHARD, D.S., BABER, N. & adults and children: 43 hepatic impairment on the
STEPHENSON, T. Should domperidone SARUWATARI, J. see HOMBHANIJE, F.W. pharmacokinetics of oral oseltamivir and
be used for the treatment of gastro- SCHAFERS, R.F. see SAEZ, A.M.O. its metabolite oseltamivir carboxylate:
oesophageal reflux in children? SCHELLEMAN, H., KLUNGEL, O.H.., 598
Systematic review of randomized VAN DUIJN, C.M., WITTEMAN, SOBUE, S., TAN, K. & HAUG-PIHALE,
controlled trials in children aged | month J.C.M., HOFMAN, A., DE BOER, A. & G. The effects of hepatic impairment on
to 11 years old: 725 CH STRICKER, B.H. Insertion/deletion the pharmacokinetics of fosfluconazole
PROCLEMER, A. see COPETTI, R. polymorphism of the ACE gene and and fluconazole following a single
PURDIE, D.M. see SORENSEN, L. adherence to ACE inhibitors: 483 intravenous bolus injection of
SCHELLENS J.H.M. see BOSCH, T.M. fosfluconazole: 160
RANKI-PESONEN, M. see LAHELMA, S. SCHELLENS, J.H.M. see DE JONGE, SORENSEN, L., STOKES, J.A., PURDIE,
RASCHE, F.M. see CZOCK, D. M.E. D.M., WOODWARD, M., ELLIOT, R. &
RAU, T. see HINZ, B. SCHMIDT, A. see HINZ, B. ROBERTS, M.S. Medication reviews in
REID, J.L. see KERNOHAN, A.F.B. SCHWAB, M. see NIEMI M. the community: results of a randomized,
REIDENBERG, M.M. Statins, lack of SCONCE, E.A., MASON, J., NOBLE, F., controlled effectiveness trial: 376
energy and ubiquinone: 606 KHAN, T.1., WYNNE, H.A. & SOUCHET, T. see VAN GANSE, E.
REITH, D. see CHUI, J. KAMALI, F. Patients with unstable SPARREBOOM, A. see ZHOU, Q.Y.
REITH, D. see GRIEVE, J. control have a poorer dietary intake of SPIEKSMA, M. see VAN KAN, H.J.M.
REITH, D. see LINGVALL, M. vitamin K compared with patients with SPINELLI, R. see VALLE, M.
RENNER, B. see HINZ, B. stable control of anticoagulation: 624 STAINSBY-TRON, M. see BOFFITO, M.
REY, E. see JULLIEN, V. SEGUIN, I. see VAN HEESWUK, R.P.G. STANLEY, A.G., JACKSON, D. &
RHODES, G.R. see CHAIKIN, P. SHAFIQ, N., MALHOTRA, S., PANDHI, BARNETT, D.B. The teaching of drug
ROBERTS, D.J. see CHAIKIN, P. P., GROVER, A. & UBOWEJA, A. A development to medical students:
ROBERTS, M.S. see SORENSEN, L. meta-analysis of clinical trials of collaboration between the pharmaceutical
ROBSON, R. see SNELL, P. paclitaxel- and sirolimus-eluting stents in industry and medical school: 464
ROCCHETTI, M. see VALLE, M. patients with obstructive coronary artery STASS, H., KUBITZA, D., MOLLER, J.-G.
RODENHUIS, S. see DE JONGE, M.E. disease: 94 & DELESEN, H. Influence of activated
ROSE, K. Better medicines for children — SHAKIR, S. see WALLER, P. charcoal on the pharmacokinetics of
where are we now, and where do we SHAW, M. see WALLER, P. moxifloxacin following intravenous and
want to be?: 657 SHAW, P.J. see NATH, C.E. oral administration of a 400mg single
ROSSI, P. see MOTOLA, D. SHENFIELD, G.M. see COCKAYNE, N.L. dose to healthy males: 536
ROUFOGALIS, B.D. see JIANG, X.M. SHENFIELD, G.M. see LOBOZ, K.K. STEINSBEKK, A. BENTZEN, N.,
ROWELL, J. see GREEN, B. SHIGA, T. see WAKAUMI, M. FONNEB®@, V. & LEWITH, G. Self
ROWELL, L. see SNELL, P. SHIN, D.-H. see SHON, J.-H. treatment with one of three self selected,
RUSHENTSOVA, U. see SAEZ, A.M.O. SHIN, J.-G. see SHON, J.-H. ultramolecular homeopathic medicines
SHON, J.-H., YOON, Y.-R., KIM, M.-J., for the prevention of upper respiratory
SAEZ, A.M.O., MOSEL, F., KIM, K.-A., LIM, Y.-C., LIU, K.-H., tract infections in children. A double-
NURNBERGER, J., RUSHENTSOVA, SHIN, D.-H., LEE, C.H., CHA, I.-J. & blind randomized placebo controlled
U., GOSSL, M., MITCHELL, A., SHIN, J.-G. Chlorpropamide 2- trial: 447
SCHAFERS, R.F., PHILIPP, T. & hydroxylation is catalysed by CYP2C9 STEPHENSON, T. How children’s responses
WENZEL, R.R. Laser Doppler imager and CYP2C19 in vitro: chlorpropamide to drugs differ from adults: 670
(LDI) scanner and intradermal injection disposition is influenced by CYP2C9, but STEPHENSON, T. see PRITCHARD, D.S.
for in vivo pharmacology in human skin not by CYP2C19 genetic polymorphism: STEWART, D., HELMS, P., McCAIG, D.,
microcirculation: responses to 552 BOND, C. & McLAY, J. Monitoring
acetylcholine, endothelin-1 and their SI, D.Y. see ZHANG, Y.F. adverse drug reactions in children using
repeatability: 511 SILVASTI, M. see LAHELMA, S. community pharmacies: a pilot study:
SAITO, M., YASUI-FURUKORI, N., UNO, SIMKIN, S. see HAWTON, K. 677
T., TAKAHATA, T., SUGAWARA, K., SIMONEAU, G. see MAHE, I. ST-MAURICE, F. see PERREAULT, S.
MUNAKATA, A. & TATEISHI, T. SIMPSON, C.R. see EKINS-DAUKES, S. STOCKIS, A. see HUSSEIN, Z.
Effects of clarithromycin on lansoprazole SIMPSON, C.R. see HELMS, P.J. STOKES, J.A. see SORENSEN, L.
pharmacokinetics between CYP2C/9 SIMPSON, C.R. see NOVAK, P.H. STRUTHERS, A. see DAVIES, J.
genotypes: 302 SIMS, EJ. see LIPWORTH, B.J. SUGAWARA, K. see SAITO, M.
760 | 59:6 | BJr Cl in Pharmacol
Author Index |
SUTTON, L. see HAWTON, K. VAN DEN BERG, L.H. see VAN KAN, WEIL, A. see SNELL, P.
SZELENYI, I. see HINZ, B. H.J.M. WENZEL, R.R. see SAEZ, A.M.O.
VAN DUIJN, C.M. see SCHELLEMAN, H. WERNER, U. see HINZ, B.
TAKAHASHI, N. see HOMBHANIJE, F.W. VAN GANSE, E., SOUCHET, T., WESTHUYZEN, J. see GREEN, B.
TAKAHATA, T. see SAITO, M. LAFOREST, L., MOULIN, P., WILLIAMS, D.B. see LADD, L.A.
TAKANO, M. see IKEDA, H. BERTRAND, M., LE JEUNNE, P., WILLIAMS, J. see NUNN, T.
TAM, S.W. see KERNOHAN, A.F.B. TRAVIER, N., YIN, D., ALEMAO, E. & WILLIAMS, K.M. see JIANG, X.M.
TAN, E.-H. see ZHOU, Q.Y. DE POUVOURVILLE, G. WILSON, K. see SNELL, P.
TAN, K. see SOBUE, S. Ineffectiveness of lipid-lowering therapy WITTEMAN, J.C.M. see SCHELLEMAN,
TAN, S. see GREIG, L.D. in primary care: 456 H.
TARRAL, A. see ASTRUC, B. VAN GERVEN, J.M.A. see DUMONT, WONG, I.C.K. & MURRAY, M.L. The
TATAMI, S. see SARASHINA, A. G.J.H. potential of UK clinical databases in
TATEISHI, T. see SAITO, M. VAN GORP, E.C.M. see KAPPELHOFF, enhancing paediatric medication research:
TAVERA, C. see MAHE, I. B.S. 750
TAYLOR, K. see LIPWORTH, B.J. VAN HEESWIIK, R.P.G., BOURBEAU, M., WONG, R.S.M. see YOU, J.H.S.
TAYLOR, M.W. see EKINS-DAUKES, S. SEGUIN, I., GIGUERE, P., GARBER, WOODCOCK, A.A. see BORRILL, Z.L.
TAYLOR, M.W. see HELMS, P.J. G.E. & CAMERON, D.W. Absence of WOODCOCK, A.A. see HOUGHTON,
TAYLOR, P.J. see ATCHESON, B.A. circadian variation in the C.M.
TEELING, M., BENNETT, K. & FEELY, J. pharmacokinetics of lopinavir/ritonavir WOODWARD, M. see SORENSEN, L.
The influence of guidelines on the use of given as a once daily dosing regimen in WORCEL, M. see KERNOHAN, A.F.B.
Statins: analysis of prescribing trends HIV-1-infected patients: 398 WRIGHT, A.W.E. see LADD, L.A.
1998-2002: 227 VAN KAN, H.J.M., GROENEVELD, G.J., WUTTKE, H. see HINZ, B.
TETT, S.E. see ATCHESON, B.A. KALMIJN, S., SPIEKSMA, M., VAN WYNNE, H.A. see SCONCE, E.A.
TILLET, Y. see MAHE, I. DEN BERG, L.H. & GUCHELAAR,
TITCHEN, T., CRANSWICK, N. & H.J. Association between CYP1A2 XIE, R. see GORDI, T.
BEGGS, S. Adverse drug reactions to activity and riluzole clearance in patients
nonsteroidal anti-inflammatory drugs, with amyotrophic lateral sclerosis: 310 YAMAGUCHI, M. see PAYNE, G.S.
COX-2 inhibitors and paracetamol in a VAN OVERMEIRE, B. see ALLEGAERT, YAMAMURA, N. see SARASHINA, A.
paediatric hospital: 718 K. YASUI-FURUKORI, N. see SAITO, M.
TOMKINS, J. see BOFFITO, M. VANMOLKOT, F.H.M. & DE HOON, YAYCIOGLU, O. see ALTAN-
TORDOFF, J. see CHUI, J. J.N.J.M. Reproducibility of forearm YAYCIOGLU, R.
TORDOFF, J. see GRIEVE, J. vasodilator response to intra-arterial YIN, D. see VAN GANSE, E.
TRAVIER, N. see VAN GANSE, E. infusion of calcitonin gene-related YOON, Y.-R. see SHON, J.-H.
TRELUYER, J.-M. see JULLIEN, V. peptide assessed by venous occlusion YOU, J.H.S., CHAN, F.W.H., WONG,
TSUDA, Y. see SARASHINA, A. plethysmography: 387 R.S.M. & CHENG, G. Is INR between
TSUKAHARA, T. see HOMBHANJE, VEROTTA, D. see CSAJKA, C. 2.0 and 3.0 the optimal level for Chinese
F.W. VEROTTA, D. see VALLE, M. patients on warfarin therapy for
TSUR, S.A. Elsevier’s dictionary of VESTBO, J. see BORRILL, Z.L. moderate-intensity anticoagulation?:
abbreviations, acronyms, synonyms and 582
symbols used in medicine, 2nd enlarged WAKAUMI, M., TSURUOKA S.,
edition: 117 SAKAMOTO, K., SHIGA, T. & ZHANG, Y.F., ZHONG, D.F., SI, D-Y.,
TSURUOKA S. see WAKAUMI, M. FUJIMURA, A. Pilsicainide in breast GUO, Y.J., CHEN, X.Y. & ZHOU, H.
TURNBULL, P. see HAWTON, K. milk from a mother: comparison with Lornoxicam pharmacokinetics in relation
disopyramide and propafenone: 120 to cytochrome P450 2C9 genotype: 14
UBOWEIJA, A. see SHAFIQ, N. WALLER, P., SHAW, M., HO, D., ZHONG, D.F. see ZHANG, Y.-F.
UNO, T. see SAITO, M. SHAKIR, S. & EBRAHIM, S. Hospital ZHOU, H. see ZHANG, Y.F.
URIEN, S. see JULLIEN, V. admissions for ‘drug-induced’ disorders ZHOU, Q.Y., SPARREBOOM, A., TAN, E.-
USUI, T. see IKEDA, H. in England: a study using the Hospital H., CHEUNG, Y.-B., LEE, A., POON,
Episodes Statistics (HES) database: 213 D., LEE, E.J.D. & CHOWBAY, B.
VAHTERISTO, M. see LAHELMA, S. WARREN, J. Obesity: weighing the risk Pharmacogenetic profiling across the
VALLE, M., SALLE, E.D., JANNUZZO, before prescribing: 259 irinotecan pathway in Asian patients with
M.G., POGGESI, I., ROCCHETTI, M., WEBB, D.J. see GREIG, L.D. cancer: 415
SPINELLI, R. & VEROTTA, D. A WEEKES, L.M., MACKSON, J.M., ZUIDEVELD, K.P. see KNIBBE, C.A.J.
predictive model for exemestane FITZGERALD, M. & PHILLIPS, S.R. ZULLINO, D.F. & KHAZAAL, Y. Increased
pharmacokinetics/pharmacodynamics National Prescribing Service: creating an risk of gastrointestinal adverse effects
incorporating the effect of food and implementation arm for national under SSRI/NSAID combination may be
formulation: 355 medicines policy: 112 due to pharmacokinetic interactions: 118
BrJ Clin Pharmacol | 59:6 | 761
British Journal of Clinical Pharmacology DOI:10.1111/).1365-2125.2005.02459.x
SUBJECT INDEX
This index was compiled from the keywords
"F MRS, 244 chemotherapy, 593 dry powder inhaler, 167
3-hydroxy-3-methylglutaryl-coenzyme A CHF3381, 405 dyslipidaemia, 456
reductase inhibitor, 291 child, 43, 674, 712, 730, 743
children, 314, 447, 677, 684, 691, 705 ebastine, 346
A, 365 Chinese patients, 582 effectiveness, 456
abacavir, 183 chlorpropamide, 552 endothelial function, 265
ABC transporters, 415 circadian, 398 endothelin-1, 511
ABCB1, 365 cirrhosis, 291 enoxaparin, 281
accommodation, 588 cisplatin, 593 enterocytes, 199
ACE gene, 483 clarithromycin, 302 enterohepatic recycling, 479
ACE inhibitors, 239, 483 clinical databases, 750 ephedra alcaloids, 335
acetylcholine, 511 clinical pharmacokinetics, 14 epidemiology, 108
activated charcoal, 536 clinical pharmacology and therapeutics, epilepsy, 712
acute coprescribing, 712 464 epileptic patient, 593
acute-phase-proteins, 233 clinical practice, 227 epinastine, 43
adult(s), 43, 183 clinical trials, 379 ETAC, 28
adverse drug reaction(s), 108, 213, 677, 718 cognition, 143 European centralised procedure, 475
AERx” iDMS, 546 community, 677 exemestane, 355
aged, 143 complementary and alternative medicines, expression, 365
allometric scaling, 705 254
amodiaquine, 298 COPD, 379 fentanyl, 249
amyl nitrite, 265 coproxamol, 207 forearm blood flow, 387
anaesthesia, 220 coronary artery disease, 94 Formulation, 674
angioedema, 233 coronary heart disease, 456 fosfluconazole, 160
angiotensin converting enzyme inhibitor, 233 coroners, 207 free drug, 271
anticancer agents, 593 C-reactive protein, 233
anticholinergic drugs, 143 creatinine clearance, 239 G2677T, 365
anticoagulant(s), 371, 425 cremophor EL, 325 gastro-oesophageal reflux, 725
antidepressants, 102 cyclooxygenase 2 inhibitors, 718 gastro-oesophageal reflux disease, 725
antihistamine, 28 cyclosporin, 18 gemfibrozil, 433
antimicrobials, 244 CYPIA2, 310 genotype, 62
antiretroviral drugs, 38 CYP2C8, 70, 62, 298 gentamicin, 54, 542
antoinduction, 189 CYP2C9, 62, 433, 552 ginger, 425
apgar, 54 CYP2C9 polymorphism, 14 ginkgo, 425
artemisinin, 189 CYP2C19, 302, 552 glucuronide, 271
asthma, 5, 152 CYP3A, 302, 440 GTN, 265
attitude, 743 cytochrome P450, 2C, 199 guidelines, 227
cytochrome P450, 3A4, 199
Bayesian estimation, 18 hepatic impairment, 160, 598
bioavailability, 80, 542 desethylamodiaquine, 298 herb—drug interactions, 425
Biomarker, 495 determinants, 564 HES data, 213
biotechnological drugs, 475 diabetes, 520, 546 HIV, 183, 398
bleeding, 371 diclofenac, 80 homeopathy, 447
body composition, 691 digoxin, 102 homoeopathy, 743
bodyweight, 183 diltiazem, 440 hospital admission, 213
Bronchodilation, 379 diuretics, 239 human small intestine, 199
budesonide, 167 domperidone, 725 hyaluronic acid, 220
bupivacaine, 220 dosage form, 674 hypertension, 520
drug development, 464
C3435T, 365 drug evaluation, 475 in vitro, 552
caffeine, 335 drug interaction(s), 38, 70, 102, 254 in vivo, 552
Calcarea carb, 447 drug metabolizing enzymes, 415 incident pain, 249
calcitonin gene-related peptide, 387 drug safety, 213 infants, 691
carboplatin, 314 drug utilization, 750 influenza, 598
case-control study, 574 drug—drug interaction, 433, 712 inhalation devices, 5
cetirizine, 28 dry eye, 588 inhalation, 542
BJr Cl in Pharmacol | 59:6 | 762-763 | 762 © 2005 Blackwell Publishing Ltd
Subject Index |
inhaled insulin, 546 off label prescribing, 712 randomized trial, 220
INR, 371 off-label, 730 rational drug use, 112
interaction, 335, 371 opioid effect, 524 registration, 730
international comparisons, 108 opthalmic insert, 220 regurgitation, 725
intestinal biopsy, 440 optimal INR, 582 renal failure, 239
intraocular pressure, 588 oral administration, 325 renal function, 314
ipratropium, 152 oscillometry, 152 renal impairment, 479
irreversible inhibition, 440 oseltamivir carboxylate, 598 renal transplant recipients, 18
oseltamivir, 598 renal transplantation, 271
ketoconazole, 346 overactive bladder, 588 reproducibility, 387
khat, 574 oxybutynin, 588 rifampicin, 199
kidney failure, 281 riluzole, 310
paclitaxel, 94, 325 ritonavir, 38, 174, 398
lansoprazole, 302 paediatric(s), 674, 718, 736, 750 rosiglitazone, 70
L-arginine, 85 paediatric dosage, 43
Laser Doppler imager, 511 paediatric population pharmacokinetics, 28 salbutamol, 5
levocetirizine, 28 paracetamol, 371, 718 saquinavir, 38
lipid-lowering agents, 456 parental, 677 scientometrics, 108
liver, 291 pediatric drug development, 657 secondary prevention, 564
lopinavir, 398 Pediatric Exclusivity, 730 self treatment, 447
loratadine, 346 persistence, 564 sepsis, 54
lornoxicam, 14 P-glycoprotein, 102, 365 sildenafil, 85
lung deposition, 167 pharmaceutical industry, 464 single nucleotide polymorphisms, 415
lungs, 542 pharmacodynamic, 355 sirolimus, 94
pharmacodynamics, 346, 546 sitafloxacin, 244
male erectile dysfunction, 85 pharmacoeconomics, 108 smoking, 574
MAO-A inhibitors, 405 pharmacoepidemiology, 102, 143 SNP, 365
MDRI1, 365 pharmacokinetic, 355 spironolactone, 520
medical education, 464 pharmacokinetic interaction, 593 SSRIs, 495
medical history taking, 254 pharmacokinetic model, 189 statin, 291, 227, 564
medicines for children, 657 pharmacokinetics, 54, 80, 160, 167, 174, stents, 94
medicines policy, 112 244, 249, 271, 281, 291, 310, 335, 346, stimulated hypercapnic response, 524
medicines, 684, 736 398, 479, 536, 546, 598, 691, 705 sublingual administration, 249
Melphalan pharmacokinetics, 314 pharmacovigilance, 213, 750 suicide, 207
meta-analysis, 94 pharmacy, 677 sulphur, 447
metabolism, 310 phase I, 495
microvascular, 511 phenotype, 62 tenofovir, 38
midazolam, 440, 691 pitavastatin, 291 theophylline, 691
model, 355 poisoning, 207 theraputic innovation, 475
modelling, 281 polymorphism, 483 tissue distribution, 691
moxifloxacin, 536 population, 355 tolterodine, 588
mycophenolic acid, 271 population pharmacokinetics, 18, 43, 183, topicsert, 220
myocardial infarction, 574 325 trimethoprim, 70
potassium salt, 80
nebulizer, 542 prescribing disease epidemiology, 684 UK, 750
neonate, 54 prescribing trends, 227 unlicensed, 730, 736
nested case-control studies, 102 prevention, 447 upper respiratory tract infection, 447, 546
neuromuscular disease, 310 primary care, 684
neuropathic pain, 405 primary health care, 712, 743 valproic acid, 593
nitric oxide, 85 primary prevention, 564 vasodilation, 387
nitroglycerine, 85 propofol, 705 venous occlusion plethysmography, 387
NMDA antagonists, 405 protein binding, 271 ventilatory depression, 524
NMI, 861, 85 Pulsatilla, 447
NONMEM, 281, 355 warfarin, 371, 425, 433, 582
nonsteroidal anti-inflammatory drugs, 239 QTe interval, 346 weight, 314
NSAID, 718 questionnaire, 677
yohimbine, 85
oesophagitis, 725 raloxifene, 479
off label, 736 randomized controlled trial, 447
Br J Clin Pharmacol | 59:6 | 763
